Drug intelligence / Profile preview

ezabenlimab + afatinib

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of ezabenlimab (BI-754091), a PD-1 immune checkpoint inhibitor, and afatinib, an irreversible ErbB family blocker that targets EGFR, HER2, and ErbB4. This combination is being investigated primarily for the treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) that has become refractory to at least one line of systemic treatment.

Brand names: Gilotrif
Other names: ezabenlimab and afatinibBI-754091 plus afatinibBI754091 plus afatinibBI 754091 plus afatinib

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)

Beyond the preview

Go deeper on ezabenlimab + afatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ezabenlimab + afatinib.

Explore the full profile